FDA Issues First Warning Letter for Drug Supply Chain Law Violations
The Food and Drug Administration recently issued its first warning letter for violations under the Drug Supply Chain Security Act, FDA Commissioner Scott Gottlieb said in a Feb. 12 statement. McKesson Corp., a U.S. distributor of pharmaceuticals, was cited for…
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
its failure to sufficiently respond to notifications from a pharmacy it supplied that there was illegitimate product in its supply chain -- opioid pills were missing from bottles that were distributed by McKesson -- and did not quarantine and investigate suspect products or maintain records of investigations of suspect product, Gottlieb said. “We’ll continue our efforts to help ensure manufacturers, repackagers, wholesale distributors, dispensers and others responsible for maintaining the supply chain are taking measurable steps under the law to appropriately track and trace medications -- including opioids -- as they move through the supply chain, and to respond to incidents involving illegitimate products in order to protect the public health,” Gottlieb said.